Dose escalation and associated economic outcomes in patients with psoriasis treated with biologics: a retrospective analysis of German health claims data
Clinical and Experimental Dermatology · 2024
DOI: 10.1093/ced/llae245 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, 2024. Verfasst von Andreas Pinter und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University of Frankfurt, Frankfurt Am Main, Germany. Hauptthemen laut MEDLINE: Psoriasis, Biological Products. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AbbVie Inc.
Abstract (Originalsprache)
Background
In Germany, several biologic therapies are available for the treatment of moderate-to-severe plaque psoriasis, with the option of exceeding recommended dosages if standard dosing does not achieve a satisfactory treatment response.
Objectives
To examine dose escalation in patients with biologic-treated psoriasis and its implications on the costs for German statutory health insurance (SHI).
Methods
We conducted a retrospective, noninterventional cohort study using German SHI health claims data from 2016 to 2021. Adult patients initiating biologic treatment were included in drug-specific cohorts. The odds for dose escalation, defined as the exceedance of the individually received daily dose over the maintenance dose recommended by the European product information, were compared between cohorts using multivariate logistic regression. The impact of dose escalation on SHI expenditure was analysed with a generalized linear model.
Results
The relative frequency of dose escalation varied between cohorts [range 1%, < 5/92 (risankizumab) to 43%, < 5/7 (infliximab)]. Compared with patients treated with risankizumab, the odds for dose escalation were statistically significantly (P < 0.05) higher in patients treated with all other biologic drugs except tildrakizumab. Patients with dose escalation during the maintenance phase accrued on average €6473 more in direct healthcare costs to SHI over a 1-year period compared with those without dose escalation, with statistical significance (P < 0.05) after controlling for differences in covariates.
Conclusions
Compared with patients treated with other biologics, dose escalation during the maintenance phase was lowest among patients treated with risankizumab. Dose escalation was associated with higher costs and thus a higher economic burden for German SHI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, University of Frankfurt, Frankfurt Am Main, Germany.
- AbbVie Inc, North Chicago, IL, USA.
- IGES Institut GmbH, Berlin, Germany.
- InGef - Institute for Applied Health Research Berlin GmbH, Berlin, Germany.
- Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Förderung
- AbbVie Inc
Zitieren
APA
Pinter, A., Soliman, A. M., Manz, K. C., Weber, V., Ludwig, P., Mocek, A., Höer, A., Richter, S. G., & Lebwohl, M. G. (2024). Dose escalation and associated economic outcomes in patients with psoriasis treated with biologics: a retrospective analysis of German health claims data. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llae245
Vancouver
Pinter A, Soliman AM, Manz KC, Weber V, Ludwig P, Mocek A, et al. Dose escalation and associated economic outcomes in patients with psoriasis treated with biologics: a retrospective analysis of German health claims data. Clinical and Experimental Dermatology. 2024. doi:10.1093/ced/llae245
BibTeX
@article{Pinter2024,
author = {Pinter, Andreas and Soliman, Ahmed M and Manz, Karina C and Weber, Valeria and Ludwig, Paul and Mocek, Anja and Höer, Ariane and Richter, Sven G and Lebwohl, Mark G},
title = {Dose escalation and associated economic outcomes in patients with psoriasis treated with biologics: a retrospective analysis of German health claims data},
journal = {Clinical and Experimental Dermatology},
year = {2024},
doi = {10.1093/ced/llae245}
}
EUVIMED